The facility's goal is to develop and maintain standardized iPSCs lines specific to a variety of rare inherited diseases — not only DBA and JMML, but
also dyskeratosis congenita, congenital dyserythropoietic anemia, thrombocytopenia absent radii (TAR), Glanzmann's thrombasthenia and Hermansky - Pudlak syndrome.